m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00735)
Target Name | hsa-miR-589-5p | ||||
---|---|---|---|---|---|
Gene Name | hsa-miR-589-5p |
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
hsa-miR-589-5p
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | METTL3 up-regulated the expression of hsa-miR-589-5p and promoted the maturation of miR-589-5p. Overexpressed miR-589-5p and METTL3 promoted the viability, migration and invasion of liver cancer cells. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Liver cancer | ICD-11: 2C12 | ||
Pathway Response | Adherens junction | hsa04520 | ||
Cell Process | Cell migration | |||
Cell invasion | ||||
In-vitro Model | THLE-2 | Normal | Homo sapiens | CVCL_3803 |
SNU-423 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0366 | |
SNU-387 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0250 | |
SNU-182 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0090 | |
SK-HEP-1 | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | |
PLC/PRF/5 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0485 | |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
In-vivo Model | The mice were fed in an SPF environment (cycle of 12-h light and 12-h dark) with a free diet. All the mice were adaptively fed for 5 days before experiments and randomly divided into the following four groups: the siNC+MC group (n = 10), the METTL3 siRNA1+MC group (n = 10), siNC+M group (n = 10) and the METTL3 siRNA1+M group (n = 10). Then, the right forelimb of mice in the siNC+MC group was subcutaneously injected with 100 uL PBS containing 1 × 106 SK-Hep1 cells co-transfected with siNC and MC; the right forelimb of mice in the METTL3 siRNA1+MC group was subcutaneously injected with 100 uL PBS containing 1 × 106 SK-Hep1 cells co-transfected with METTL3 siRNA1 and MC; the right forelimb of mice in the siNC+M group was subcutaneously injected with 100 uL PBS containing 1 × 106 SK-Hep1 cells co-transfected with siNC and M; the right forelimb of mice in the METTL3 siRNA1+M group was subcutaneously injected with 100 uL PBS containing 1 × 106 SK-Hep1 cells co-transfected with METTL3 siRNA1 and M. | |||
Liver cancer [ICD-11: 2C12]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | METTL3 up-regulated the expression of hsa-miR-589-5p and promoted the maturation of miR-589-5p. Overexpressed miR-589-5p and METTL3 promoted the viability, migration and invasion of liver cancer cells. | |||
Responsed Disease | Liver cancer [ICD-11: 2C12] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Pathway Response | Adherens junction | hsa04520 | ||
Cell Process | Cell migration | |||
Cell invasion | ||||
In-vitro Model | THLE-2 | Normal | Homo sapiens | CVCL_3803 |
SNU-423 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0366 | |
SNU-387 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0250 | |
SNU-182 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0090 | |
SK-HEP-1 | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens | CVCL_0525 | |
PLC/PRF/5 | Adult hepatocellular carcinoma | Homo sapiens | CVCL_0485 | |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
In-vivo Model | The mice were fed in an SPF environment (cycle of 12-h light and 12-h dark) with a free diet. All the mice were adaptively fed for 5 days before experiments and randomly divided into the following four groups: the siNC+MC group (n = 10), the METTL3 siRNA1+MC group (n = 10), siNC+M group (n = 10) and the METTL3 siRNA1+M group (n = 10). Then, the right forelimb of mice in the siNC+MC group was subcutaneously injected with 100 uL PBS containing 1 × 106 SK-Hep1 cells co-transfected with siNC and MC; the right forelimb of mice in the METTL3 siRNA1+MC group was subcutaneously injected with 100 uL PBS containing 1 × 106 SK-Hep1 cells co-transfected with METTL3 siRNA1 and MC; the right forelimb of mice in the siNC+M group was subcutaneously injected with 100 uL PBS containing 1 × 106 SK-Hep1 cells co-transfected with siNC and M; the right forelimb of mice in the METTL3 siRNA1+M group was subcutaneously injected with 100 uL PBS containing 1 × 106 SK-Hep1 cells co-transfected with METTL3 siRNA1 and M. | |||